AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19681777 — intervention group
Group type: EXPERIMENTAL
Intervention: Acustimulation (active ReliefBand device at P6 acupoint)
Number of subjects: 200
Study 19681777 — intervention group
Group type: COMPARATOR
Intervention: Sham group (inactive device)
Number of subjects: 200
Study 18054750 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 6414
Study 18054750 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the PPI dose
Number of subjects: 6414
Study 18054750 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 6414
Study 18054750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 6414
Study 18054750 — intervention group
Group type: COMPARATOR
Intervention: Histamine‐2 receptor antagonists (H2RAs)
Number of subjects: 6414
Study 18054750 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 6414
Study 18054750 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 6414
Study 16421072 — intervention group
Group type: EXPERIMENTAL
Intervention: M3S-based head-controlled wheelchair system
Number of subjects: 10
Study 16421072 — intervention group
Group type: COMPARATOR
Intervention: Head-controlled wheelchair system without M3S standard
Number of subjects: 10
Study 12201616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 1289
Study 12201616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 2 mg
Number of subjects: 1289
Study 12201616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin ER 5 mg
Number of subjects: 1289
Study 12201616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin ER 10 mg
Number of subjects: 1289
Study 9651262 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 24
Study 9651262 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 24
Study 9651262 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of trial results
Number of subjects: 24
Study 8608057 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measurement tools
Number of subjects: 0
Study 8608057 — intervention group
Group type: COMPARATOR
Intervention: Phase III randomized controlled trials
Number of subjects: 0
Study 2231756 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 2231756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 479006 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day for three days preoperatively and three weeks postoperatively)
Number of subjects: 42
Study 479006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical schedule to indomethacin group)
Number of subjects: 42
Study 31156083 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended course (EC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, tapering from 60 mg/m2 on alternate days for weeks 5-16 (total 3150 mg/m2)
Number of subjects: 237
Study 31156083 — intervention group
Group type: COMPARATOR
Intervention: Standard course (SC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, 40 mg/m2 on alternate days for weeks 5-8, and matching placebo for weeks 9-18 (total 2240 mg/m2)
Number of subjects: 237
Study 31156083 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended course (EC) prednisolone therapy
Number of subjects: 237
Study 31156083 — intervention group
Group type: COMPARATOR
Intervention: Standard course (SC) prednisolone therapy
Number of subjects: 237
Study 29936923 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg/d as Se yeast)
Number of subjects: 53
Study 27160610 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional method
Number of subjects: 90
Study 27160610 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist pivot method
Number of subjects: 90
Study 27160610 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral method
Number of subjects: 90
Study 25346332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Infusions (CI) at 4°C, 2L at 4L/h
Number of subjects: 20
Study 25346332 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal Cooling (NPC) at 60L/min for 1 h
Number of subjects: 20
Study 25346332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Infusions (CI)
Number of subjects: 20
Study 25346332 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal Cooling (NPC)
Number of subjects: 20
Study 22678327 — intervention group
Group type: EXPERIMENTAL
Intervention: HES+E
Number of subjects: 49
Study 22678327 — intervention group
Group type: COMPARATOR
Intervention: NS+E
Number of subjects: 49
Study 21036445 — intervention group
Group type: EXPERIMENTAL
Intervention: Employer Perspective Scale (EPS) administered to employers regarding hiring people with health conditions
Number of subjects: 100
Study 21036445 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma measures including attributions about disease onset and offset
Number of subjects: 100
Study 21036445 — intervention group
Group type: COMPARATOR
Intervention: Employer perspectives in Chicago
Number of subjects: 100
Study 21036445 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of benefits of hiring people with health conditions
Number of subjects: 100
Study 17429183 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy program workshop led by a dentist
Number of subjects: 63
Study 15705374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-carnitine (2 g/day) for 3 months
Number of subjects: 30
Study 15705374 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 30
Study 12431966 — intervention group
Group type: EXPERIMENTAL
Intervention: TNP-470 at 60 mg/m² three times per week and paclitaxel at 225 mg/m² administered over 3 hours every 3 weeks
Number of subjects: 32
Study 12431966 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 32
Study 10601925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicardipine (40 mg loading dose, then 20 mg every 2 hours as needed, total 80 mg)
Number of subjects: 122
Study 10601925 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate (6 g bolus followed by 2 to 4 g/h)
Number of subjects: 122
Study 7677557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/d)
Number of subjects: 245
Study 7677557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 2206826 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg) and nifedipine retard (20 mg) once daily
Number of subjects: 30
Study 2206826 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg once daily)
Number of subjects: 30
Study 2206826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol and nifedipine
Number of subjects: 30
Study 113074 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 rad in 8 fractions over 10 days with intravenous 5 Fluorouracil (5 F.U.) at a dose of 500 mg daily x 4 days preirradiation and then 12.5 mg/kg daily for 5 days every 28 days for six courses.
Number of subjects: 142
Study 113074 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and 5 F.U. in the same schedule as Division I.
Number of subjects: 142
Study 113074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa 45 mg intravenously daily for three days and then every 28 days for 6 months.
Number of subjects: 142
Study 113074 — intervention group
Group type: COMPARATOR
Intervention: Quality of life assessment.
Number of subjects: 142
Study 31791552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ralimetinib (200 mg Q12H) + Gemcitabine (1000 mg/m2 on Days 3 and 10) + Carboplatin (AUC 4 on Day 3)
Number of subjects: 118
Study 31791552 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Gemcitabine (1000 mg/m2 on Days 3 and 10) + Carboplatin (AUC 4 on Day 3)
Number of subjects: 118
Study 31791552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ralimetinib (200 mg Q12H) + Gemcitabine + Carboplatin
Number of subjects: 118
Study 31791552 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Gemcitabine + Carboplatin
Number of subjects: 118
Study 31719658 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal ratio ventilation (ERV) of 1:1
Number of subjects: 50
Study 31719658 — intervention group
Group type: COMPARATOR
Intervention: Conventional ratio ventilation (CRV) of 1:2
Number of subjects: 50
Study 29265873 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information plus mental contrasting with implementation intentions (MCII)
Number of subjects: 183
Study 29265873 — intervention group
Group type: COMPARATOR
Intervention: Unstructured information
Number of subjects: 183
Study 29265873 — intervention group
Group type: COMPARATOR
Intervention: Structured information
Number of subjects: 183
Study 24852938 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) 5%
Number of subjects: 100
Study 24852938 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) 10%
Number of subjects: 100
Study 24852938 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) 15%
Number of subjects: 100
Study 24852938 — intervention group
Group type: COMPARATOR
Intervention: Synthetic astaxanthin (PC)
Number of subjects: 100
Study 24852938 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) (0%)
Number of subjects: 100
Study 22506756 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked words that were semantically related to the target word
Number of subjects: 0
Study 22506756 — intervention group
Group type: COMPARATOR
Intervention: Masked words that were semantically unrelated to the target word
Number of subjects: 0
Study 20691441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-angle volar-locked plates
Number of subjects: 56
Study 20691441 — intervention group
Group type: COMPARATOR
Intervention: Manipulation and Kirschner wires
Number of subjects: 56
Study 19783792 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation in family nursing
Number of subjects: 0
Study 16892265 — intervention group
Group type: EXPERIMENTAL
Intervention: Red mixed berry juice (700 mL daily, TEAC: 19.1 mmol/L trolox)
Number of subjects: 18
Study 16892265 — intervention group
Group type: COMPARATOR
Intervention: Control juice (polyphenol-depleted, TEAC: 2.4 mmol/L trolox)
Number of subjects: 18
Study 15242204 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaving
Number of subjects: 90
Study 15242204 — intervention group
Group type: COMPARATOR
Intervention: Not shaving
Number of subjects: 90
Study 11380306 — intervention group
Group type: EXPERIMENTAL
Intervention: simple educational intervention
Number of subjects: 114
Study 11380306 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 114
Study 9378844 — intervention group
Group type: EXPERIMENTAL
Intervention: YM90K (36 mg single dose, 24 mg repeated dose over 3 hours)
Number of subjects: 0
Study 9378844 — intervention group
Group type: EXPERIMENTAL
Intervention: YM90K (24 mg repeated doses)
Number of subjects: 0
Study 9378844 — intervention group
Group type: EXPERIMENTAL
Intervention: YM90K
Number of subjects: 0
Study 8105723 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 48
Study 8105723 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 48
Study 8105723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2948280 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone
Number of subjects: 11
Study 2948280 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 2948280 — intervention group
Group type: EXPERIMENTAL
Intervention: sleep loss
Number of subjects: 11
Study 31116893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupine positioning (NSP)
Number of subjects: 11480
Study 31116893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupine positioning (NSP) with direct laryngoscopy
Number of subjects: 11480
Study 31116893 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning (SP)
Number of subjects: 11480
Study 28931500 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Remediation Therapy (CogRem)
Number of subjects: 86
Study 28931500 — intervention group
Group type: COMPARATOR
Intervention: Internet-based control condition (WebInfo)
Number of subjects: 86
Study 25742919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv 250 mg
Number of subjects: 32
Study 25742919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv 500 mg
Number of subjects: 32
Study 25742919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23361389 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to and treatment by a trained dietitian
Number of subjects: 146
Study 23361389 — intervention group
Group type: COMPARATOR
Intervention: No referral (control group)
Number of subjects: 146
Study 21654700 — intervention group
Group type: EXPERIMENTAL
Intervention: Richly micronutrient-fortified porridge
Number of subjects: 743
Study 21654700 — intervention group
Group type: COMPARATOR
Intervention: Basal micronutrient-fortified porridge
Number of subjects: 743
Study 18445099 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic-guided nasal anesthesia (EGNA)
Number of subjects: 235
Study 18445099 — intervention group
Group type: COMPARATOR
Intervention: Cotton-tipped applicator nasal anesthesia (CTNA)
Number of subjects: 235
Study 16511336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the left temporo-parietal cortex
Number of subjects: 16
Study 16511336 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz rTMS over the right temporo-parietal cortex
Number of subjects: 16
Study 16511336 — intervention group
Group type: COMPARATOR
Intervention: Sham position
Number of subjects: 16
Study 15276536 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depletion (LD) group
Number of subjects: 32
Study 15276536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 11518200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (25 g/d providing 7.5 g n-3 LCPUFAs)
Number of subjects: 10
Study 11518200 — intervention group
Group type: COMPARATOR
Intervention: High-oleic sunflower oil (25 g/d providing 22 g monounsaturated fatty acids)
Number of subjects: 10
Study 11518200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 10
Study 11518200 — intervention group
Group type: COMPARATOR
Intervention: High-oleic sunflower oil
Number of subjects: 10
Study 9545673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefopzopran (CZOP) 25.0 mg/kg
Number of subjects: 2
Study 9545673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefopzopran (CZOP) 20.0 mg/kg
Number of subjects: 2
Study 9545673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefopzopran (CZOP) 18.75 mg/kg
Number of subjects: 2
Study 8296253 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education programme (3 hours)
Number of subjects: 76
Study 8296253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 3731682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg po q.i.d. for 2 weeks)
Number of subjects: 9
Study 27652679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (taken regularly or as needed)
Number of subjects: 1365
Study 27652679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1365
Study 26565136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin/chlorhexidine
Number of subjects: 793
Study 26565136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study 24917631 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus osteopathic manipulative treatment (SC+OMT)
Number of subjects: 52
Study 24917631 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (SCO)
Number of subjects: 52
Study 22500846 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing intervention
Number of subjects: 23
Study 22500846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 20534420 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + CRT
Number of subjects: 164
Study 20534420 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 164
Study 18445141 — intervention group
Group type: EXPERIMENTAL
Intervention: AGN 201904‐Z (600 mg/day)
Number of subjects: 24
Study 18445141 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (40 mg/day)
Number of subjects: 24
Study 16324138 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized anesthesia delivery system (Wand)
Number of subjects: 125
Study 16324138 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 125
Study 12624625 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (0.3‐100 IU/min)
Number of subjects: 19
Study 12624625 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (2‐8 pmol/min)
Number of subjects: 19
Study 12624625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (100‐1000 pmol/min)
Number of subjects: 19
Study 12624625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2‐8 micro g/min)
Number of subjects: 19
Study 12624625 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 19
Study 11576031 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-medications program
Number of subjects: 1356
Study 11576031 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-therapy program
Number of subjects: 1356
Study 11576031 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356
Study 9133763 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS‐Cog subtest scores
Number of subjects: 1648
Study 9133763 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation item of ADAS‐Cog
Number of subjects: 1648
Study 7699226 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 57
Study 7699226 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation
Number of subjects: 57
Study 3581030 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP with intermediate dose methotrexate
Number of subjects: 73
Study 3581030 — intervention group
Group type: COMPARATOR
Intervention: CHOP without intermediate dose methotrexate
Number of subjects: 73
Study 28571713 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched familiar foods and drinks (intervention group, n=67)
Number of subjects: 147
Study 28571713 — intervention group
Group type: COMPARATOR
Intervention: Standard energy and protein rich hospital menu (control group, n=80)
Number of subjects: 147
Study 27553664 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA cement
Number of subjects: 36
Study 27553664 — intervention group
Group type: COMPARATOR
Intervention: Gutta-percha and root canal sealer
Number of subjects: 36
Study 24341973 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation by an anonymous peer
Number of subjects: 0
Study 24341973 — intervention group
Group type: COMPARATOR
Intervention: Alone (no observation)
Number of subjects: 0
Study 24032188 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Naoqing Xue (Extra)
Number of subjects: 146
Study 24032188 — intervention group
Group type: COMPARATOR
Intervention: Control group (acupuncture at Jiexi, Yanglingquan, and Sanyinjiao)
Number of subjects: 146
Study 20098350 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise program (n = 56)
Number of subjects: 105
Study 20098350 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (n = 49)
Number of subjects: 105
Study 18410447 — intervention group
Group type: EXPERIMENTAL
Intervention: MyVTD (bortezomib, thalidomide, dexamethasone, and liposomal doxorubicin)
Number of subjects: 70
Study 18410447 — intervention group
Group type: COMPARATOR
Intervention: VTD (bortezomib, thalidomide, and dexamethasone)
Number of subjects: 70
Study 16780650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (HG) in HOCM (n=14)
Number of subjects: 60
Study 16780650 — intervention group
Group type: COMPARATOR
Intervention: Non-hydration group (NHG) in HOCM (n=13)
Number of subjects: 60
Study 16780650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (HG) in LOCM (n=18)
Number of subjects: 60
Study 16780650 — intervention group
Group type: COMPARATOR
Intervention: Non-hydration group (NHG) in LOCM (n=15)
Number of subjects: 60
Study 12823235 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (30 micro g/ml zinc)
Number of subjects: 204
Study 12823235 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (80 micro g/ml zinc)
Number of subjects: 204
Study 12823235 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 204
Study 11728289 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 304
Study 11728289 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 32 mg (with hydrochlorothiazide 12.5 mg if DBP was 90 mmHg or higher at week 8)
Number of subjects: 304
Study 11728289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 11728289 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 304
Study 11728289 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil and hydrochlorothiazide
Number of subjects: 304
Study 8840098 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin (200,000 U.I.C. as intravenous bolus injection)
Number of subjects: 15
Study 8840098 — intervention group
Group type: COMPARATOR
Intervention: placebo (10 ml isotonic saline)
Number of subjects: 15
Study 1538302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 5 mg/kg
Number of subjects: 27
Study 1538302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg/kg
Number of subjects: 27
Study 1538302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 7.5 mg/kg
Number of subjects: 27
Study 1538302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 15 mg/kg
Number of subjects: 27
Study 30753623 — intervention group
Group type: EXPERIMENTAL
Intervention: L-histidine injection (0.55 mg in 200 μL 0.75% saline)
Number of subjects: 3
Study 30753623 — intervention group
Group type: EXPERIMENTAL
Intervention: L-histidine injection
Number of subjects: 3